Last reviewed · How we verify
Normal Saline Flush
Normal saline flush maintains vascular access patency by delivering sterile isotonic sodium chloride solution through catheters or IV lines.
Normal Saline Flush, marketed by Yasser S Mostafa, MD, is a widely used solution in medical settings, though specific revenue figures are not provided. The key composition patent is set to expire in 2028, which may provide a competitive advantage until then. The primary risk is the potential for increased competition post-patent expiry.
At a glance
| Generic name | Normal Saline Flush |
|---|---|
| Also known as | 0.9% isotonic normal saline, placebo comparator, Group 2 |
| Sponsor | Yasser S Mostafa, MD |
| Modality | Small molecule |
| Therapeutic area | Supportive Care / Medical Device Support |
| Phase | FDA-approved |
Mechanism of action
Normal saline (0.9% sodium chloride) is an isotonic crystalloid solution that matches plasma osmolality, preventing hemolysis or cell crenation. It is used to keep intravenous catheters, central lines, and other vascular access devices patent between medication administrations or blood draws, and can be used for gentle flushing to prevent clot formation and maintain line integrity.
Approved indications
- Maintenance of intravenous catheter patency
- Vascular access device flushing
- Prevention of thrombosis in central lines and peripheral IV lines
Common side effects
- Phlebitis or irritation at injection site
- Infection (if aseptic technique not followed)
- Fluid overload (with excessive volume)
Key clinical trials
- FAP-targeted PET/NIR in Lung Malignant Tumors
- Indocyanine Green Fluorescence Angiography (ICG-FA) in Revisional Bariatric Surgery (NA)
- Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors
- A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients (PHASE2, PHASE3)
- Evaluation of Endobronchial Ultrasound Needle Cleaning Techniques and Their Impact on Specimen Contamination (NA)
- Hyperpolarized MRSI in Ischemic Heart Disease: A Metabolic Investigation of the Heart Muscle
- Adenosine vs. Diltiazem (PHASE4)
- Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Normal Saline Flush CI brief — competitive landscape report
- Normal Saline Flush updates RSS · CI watch RSS
- Yasser S Mostafa, MD portfolio CI